Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
PurposeNeoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM). This analysis was aimed at real-world vali...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Breast cancer research and treatment
Year: 2018, Volume: 173, Issue: 2, Pages: 319-328 |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-018-5008-3 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1007/s10549-018-5008-3
|
| Author Notes: | Peter A. Fasching · Andreas D. Hartkopf · Paul Gass · Lothar Häberle · Leyla Akpolat‑Basci · Alexander Hein · Bernhard Volz · Florin‑Andrei Taran · Naiba Nabieva · Birgit Pott · Friedrich Overkamp · Hanna Einarson · Peyman Hadji · Hans Tesch · Johannes Ettl · Diana Lüftner · Markus Wallwiener · Volkmar Müller · Wolfgang Janni · Tanja N. Fehm · Andreas Schneeweiss · Michael Untch · Dirk Pott · Michael P. Lux · Thomas Geyer · Cornelia Liedtke · Harald Seeger · Sarah Wetzig · Arndt Hartmann · Rüdiger Schulz‑Wendtland · Erik Belleville · Diethelm Wallwiener · Matthias W. Beckmann · Sara Y. Brucker · Hans‑Christian Kolberg |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1667904604 | ||
| 003 | DE-627 | ||
| 005 | 20250322005745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190625r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-018-5008-3 |2 doi | |
| 035 | |a (DE-627)1667904604 | ||
| 035 | |a (DE-599)KXP1667904604 | ||
| 035 | |a (OCoLC)1341229058 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fasching, Peter Andreas |d 1975- |e VerfasserIn |0 (DE-588)129068780 |0 (DE-627)388703040 |0 (DE-576)297477099 |4 aut | |
| 245 | 1 | 0 | |a Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer |b a multicentric analysis |c Peter A. Fasching · Andreas D. Hartkopf · Paul Gass · Lothar Häberle · Leyla Akpolat‑Basci · Alexander Hein · Bernhard Volz · Florin‑Andrei Taran · Naiba Nabieva · Birgit Pott · Friedrich Overkamp · Hanna Einarson · Peyman Hadji · Hans Tesch · Johannes Ettl · Diana Lüftner · Markus Wallwiener · Volkmar Müller · Wolfgang Janni · Tanja N. Fehm · Andreas Schneeweiss · Michael Untch · Dirk Pott · Michael P. Lux · Thomas Geyer · Cornelia Liedtke · Harald Seeger · Sarah Wetzig · Arndt Hartmann · Rüdiger Schulz‑Wendtland · Erik Belleville · Diethelm Wallwiener · Matthias W. Beckmann · Sara Y. Brucker · Hans‑Christian Kolberg |
| 264 | 1 | |c 2019 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First online: 15 October 2018 | ||
| 500 | |a Gesehen am 25.06.2019 | ||
| 520 | |a PurposeNeoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM). This analysis was aimed at real-world validation of these results from prospective randomized trials.MethodsIn a retrospective analysis conducted in the PRAEGNANT network, patients were eligible for inclusion if they had either received neoadjuvant therapy with CTX/TZM or chemotherapy, trastuzumab, and pertuzumab (CTX/TZM/PTZ) and subsequently underwent surgery for their primary breast cancer. The effect of the two neoadjuvant regimens on pCR in addition to commonly applicable predictors of pCR was analyzed in 300 patients from three study sites, using logistic regression analyses with treatment arm, age, clinical tumor stage, grading, and hormone receptor status as predictors.ResultspCR with complete disappearance of all tumor cells was seen in 30.2% (n = 58) of patients treated with CTX/TZM and in 52.8% (n = 57) of those treated with CTX/TZM/PTZ. CTX/TZM/PTZ was positively associated with pCR (adjusted odds ratio 2.44; 95% CI 1.49-4.02). Mastectomy rates were not influenced by the therapy.ConclusionsThe results of clinical trials were confirmed in this dataset of patients who were treated outside of clinical trials in everyday routine work. pCR rates can be improved by 20% with pertuzumab in routine clinical use. | ||
| 534 | |c 2018 | ||
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Neoadjuvant | |
| 650 | 4 | |a pCR | |
| 650 | 4 | |a Pertuzumab | |
| 650 | 4 | |a Real-world data | |
| 650 | 4 | |a Registry | |
| 650 | 4 | |a Trastuzumab | |
| 700 | 1 | |a Hartkopf, Andreas D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gass, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Häberle, Lothar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Akpolat-Basci, Leyla |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hein, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Volz, Bernhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taran, Florin-Andrei |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nabieva, Naiba |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pott, Birgit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Overkamp, Friedrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Einarson, Hanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hadji, Peyman |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tesch, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ettl, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lüftner, Diana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wallwiener, Markus |d 1980- |e VerfasserIn |0 (DE-588)134044827 |0 (DE-627)692043934 |0 (DE-576)27468327X |4 aut | |
| 700 | 1 | |a Müller, Volkmar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Janni, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Fehm, Tanja |d 1971- |e VerfasserIn |0 (DE-588)120391759 |0 (DE-627)080645690 |0 (DE-576)292194064 |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Untch, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pott, Dirk |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lux, Michael P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geyer, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Liedtke, Cornelia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seeger, Harald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wetzig, Sarah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hartmann, Arndt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schulz-Wendtland, Rüdiger |e VerfasserIn |4 aut | |
| 700 | 1 | |a Belleville, Erik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wallwiener, Diethelm |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beckmann, Matthias W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brucker, Sara Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kolberg, Hans-Christian |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 1981 |g 173(2019), 2, Seite 319-328 |h Online-Ressource |w (DE-627)320433722 |w (DE-600)2004077-5 |w (DE-576)104194162 |x 1573-7217 |7 nnas |a Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer a multicentric analysis |
| 773 | 1 | 8 | |g volume:173 |g year:2019 |g number:2 |g pages:319-328 |g extent:10 |a Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer a multicentric analysis |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10549-018-5008-3 |x Verlag |x Resolving-System |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20190625 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 21 | ||
| 998 | |g 134044827 |a Wallwiener, Markus |m 134044827:Wallwiener, Markus |d 910000 |d 910400 |e 910000PW134044827 |e 910400PW134044827 |k 0/910000/ |k 1/910000/910400/ |p 17 | ||
| 999 | |a KXP-PPN1667904604 |e 3489641086 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Fasching, Peter Andreas","family":"Fasching","given":"Peter Andreas","role":"aut"},{"role":"aut","given":"Andreas D.","display":"Hartkopf, Andreas D.","family":"Hartkopf"},{"family":"Gass","display":"Gass, Paul","given":"Paul","role":"aut"},{"role":"aut","given":"Lothar","family":"Häberle","display":"Häberle, Lothar"},{"role":"aut","given":"Leyla","display":"Akpolat-Basci, Leyla","family":"Akpolat-Basci"},{"family":"Hein","display":"Hein, Alexander","given":"Alexander","role":"aut"},{"display":"Volz, Bernhard","family":"Volz","role":"aut","given":"Bernhard"},{"given":"Florin-Andrei","role":"aut","family":"Taran","display":"Taran, Florin-Andrei"},{"given":"Naiba","role":"aut","family":"Nabieva","display":"Nabieva, Naiba"},{"given":"Birgit","role":"aut","family":"Pott","display":"Pott, Birgit"},{"family":"Overkamp","display":"Overkamp, Friedrich","role":"aut","given":"Friedrich"},{"role":"aut","given":"Hanna","family":"Einarson","display":"Einarson, Hanna"},{"role":"aut","given":"Peyman","family":"Hadji","display":"Hadji, Peyman"},{"display":"Tesch, Hans","family":"Tesch","role":"aut","given":"Hans"},{"family":"Ettl","display":"Ettl, Johannes","role":"aut","given":"Johannes"},{"display":"Lüftner, Diana","family":"Lüftner","role":"aut","given":"Diana"},{"given":"Markus","role":"aut","family":"Wallwiener","display":"Wallwiener, Markus"},{"given":"Volkmar","role":"aut","family":"Müller","display":"Müller, Volkmar"},{"role":"aut","given":"Wolfgang","display":"Janni, Wolfgang","family":"Janni"},{"given":"Tanja","role":"aut","display":"Fehm, Tanja","family":"Fehm"},{"given":"Andreas","role":"aut","family":"Schneeweiss","display":"Schneeweiss, Andreas"},{"display":"Untch, Michael","family":"Untch","role":"aut","given":"Michael"},{"family":"Pott","display":"Pott, Dirk","given":"Dirk","role":"aut"},{"role":"aut","given":"Michael P.","family":"Lux","display":"Lux, Michael P."},{"given":"Thomas","role":"aut","display":"Geyer, Thomas","family":"Geyer"},{"family":"Liedtke","display":"Liedtke, Cornelia","given":"Cornelia","role":"aut"},{"family":"Seeger","display":"Seeger, Harald","given":"Harald","role":"aut"},{"display":"Wetzig, Sarah","family":"Wetzig","given":"Sarah","role":"aut"},{"given":"Arndt","role":"aut","family":"Hartmann","display":"Hartmann, Arndt"},{"display":"Schulz-Wendtland, Rüdiger","family":"Schulz-Wendtland","role":"aut","given":"Rüdiger"},{"family":"Belleville","display":"Belleville, Erik","given":"Erik","role":"aut"},{"given":"Diethelm","role":"aut","display":"Wallwiener, Diethelm","family":"Wallwiener"},{"role":"aut","given":"Matthias W.","family":"Beckmann","display":"Beckmann, Matthias W."},{"display":"Brucker, Sara Y.","family":"Brucker","given":"Sara Y.","role":"aut"},{"given":"Hans-Christian","role":"aut","display":"Kolberg, Hans-Christian","family":"Kolberg"}],"language":["eng"],"note":["First online: 15 October 2018","Gesehen am 25.06.2019"],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer","subtitle":"a multicentric analysis","title_sort":"Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer"}],"recId":"1667904604","physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Peter A. Fasching · Andreas D. Hartkopf · Paul Gass · Lothar Häberle · Leyla Akpolat‑Basci · Alexander Hein · Bernhard Volz · Florin‑Andrei Taran · Naiba Nabieva · Birgit Pott · Friedrich Overkamp · Hanna Einarson · Peyman Hadji · Hans Tesch · Johannes Ettl · Diana Lüftner · Markus Wallwiener · Volkmar Müller · Wolfgang Janni · Tanja N. Fehm · Andreas Schneeweiss · Michael Untch · Dirk Pott · Michael P. Lux · Thomas Geyer · Cornelia Liedtke · Harald Seeger · Sarah Wetzig · Arndt Hartmann · Rüdiger Schulz‑Wendtland · Erik Belleville · Diethelm Wallwiener · Matthias W. Beckmann · Sara Y. Brucker · Hans‑Christian Kolberg"]},"id":{"eki":["1667904604"],"doi":["10.1007/s10549-018-5008-3"]},"relHost":[{"disp":"Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer a multicentric analysisBreast cancer research and treatment","part":{"issue":"2","extent":"10","volume":"173","year":"2019","text":"173(2019), 2, Seite 319-328","pages":"319-328"},"origin":[{"publisher":"Springer Science + Business Media B.V. ; Kluwer","dateIssuedKey":"1981","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","dateIssuedDisp":"1981-"}],"note":["Gesehen am 02.12.05","Fortsetzung der Druck-Ausgabe"],"title":[{"title_sort":"Breast cancer research and treatment","title":"Breast cancer research and treatment"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"320433722","pubHistory":["1.1981 -"],"id":{"issn":["1573-7217"],"eki":["320433722"],"zdb":["2004077-5"]}}]} | ||
| SRT | |a FASCHINGPEEFFICACYOF2019 | ||